Back to Agenda
Session 2: Physician’s Challenges – Treatment Pathways
Session Chair(s)
Sam Khalil
Worldwide Head of Medical Affairs, Immunology, Hepatology and Dermatology, Novartis, Switzerland
Speaker(s)
Biologic Medicines – The New Normal
Sam Khalil
Worldwide Head of Medical Affairs, Immunology, Hepatology and Dermatology, Novartis, Switzerland
Immunogenicity – The Wrong Elephant in the Room
Paul Chamberlain
Biopharmaceuticals & Immunogenicity Expert, NDA Advisory Board, United Kingdom
The NOR-SWITCH Study
Kristin Kaasen Jørgensen, MD, PhD
Gastroenterologist, Akershus University Hospital, Norway
ESNO Guideline: Switch Management Between Similar Biological Medicines
Hanneke Voorneveld
Nurse Practitioner Rheumatology, Maasstad Hospital, Netherlands
Have an account?